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Blood, lymphoid tissues, and placenta contain diverse subpopulations of natural killer (NK) cells that possess
distinct immune functions. Recent studies have shown that human and mouse gut-associated lymphoid
tissues harbor a unique NK cell subset that specializes in production of interleukin (IL)-22. This cytokine plays
a role in host defense of mucosal barriers, although dysregulated secretion may cause autoimmune disease.
In parallel, human fetal lymphoid tissue inducer (LTi) cells and mouse adult LTi-like cells in secondary
lymphoid tissues were found to release IL-22, as well as IL-17, a proinflammatory cytokine that mediates
host defense against extracellular pathogens. Here, we compare these recently identified immune cells,
reviewingwhat is known about their anatomical location, differentiation requirements, function, and potential
involvement in host defense and autoimmunity. Finally, we discuss the challenges faced in furthering our
understanding of the developmental relationships and role of NK and LTi-like cells in mucosal immune
responses.Natural Killer Cells: The Classical View
Natural killer (NK) cells are innate lymphocytes that provide first-
line defense against a range of viruses and tumors, typically
functioning through two major mechanisms: (1) lysis of infected
cells through release of perforin and granzymes or expression
of death receptor ligands; (2) activation of other immune cell
types through secretion of interferon (IFN)-g and other cytokines.
NK cell-mediated immunosurveillance relies on the expression
of germline-encoded receptors, including Ly49s, KIRs, CD94-
NKG2A and CD94-NKG2C dimers, NKG2D, 2B4, NKp46,
NKp44, and NKp30, all of which possess well-defined ligand-
binding repertoires (Lanier, 2008). NK cells simultaneously
express an array of receptors that are categorized as either acti-
vating or inhibitory. Several of the activating receptors recognize
major histocompatibility complex (MHC) class I-like molecules
that are encoded by pathogens and expressed on pathogen-in-
fected cells (Scalzo and Yokoyama, 2008). Additional activating
receptors recognize endogenous MHC class I-like molecules
that are expressed only in the context of infection, DNA damage,
or stress (Gasser and Raulet, 2006). Inhibitory receptors recog-
nize MHC class I molecules and other cell-surface molecules,
essentially setting the threshold for NK cell activation. If path-
ogen-infected or tumor cells lose expression of inhibitory ligands
(a phenomenon known as ‘‘missing-self’’), NK cells are released
from inhibition and accordingly become capable of killing the
affected cell (Karre, 2002). Therefore, triggering of NK cell
effector functions is the result of the integration of multiple
activating and inhibitory signals (Bryceson and Long, 2008).
The magnitude of NK cell responses against infected or
malignant cells is also dependent on alarm signals, which are
released by sentinel immune cells, including dendritic cells
(DCs), macrophages, and plasmacytoid DCs, as well as path-
ogen-infected tissues (Biron, 2001). These signals include type
I IFNs (i.e., IFN-a and IFN-b), IL-12, IL-18, and IL-15, all of whichenhance the lytic potential of NK cells and their ability to produce
IFN-g.
NK Cell Diversity in Blood, Lymphoid Tissues,
and Placenta
Initially, human NK cells were classified into two subsets, on the
basis of the degree of expression of the adhesionmolecule CD56
(Caligiuri, 2008). CD56dim NK cells represent the vast majority
of blood NK cells but are rare in the lymph nodes, whereas
CD56bright NK cells are predominant in secondary lymphoid
tissues such as lymph nodes and tonsils. CD56bright andCD56dim
NK cells display distinct repertoires of inhibitory and activating
receptors, utilize disparate adhesion molecules and chemokine
receptors for homing, respond differently to IL-2, and, most
importantly, demonstrate unique effector functions. Whereas
CD56bright NK cells preferentially secrete IFN-g, CD56dim NK
cells are almost exclusively cytotoxic. Recent studies have
proposed that these subsets represent two sequential stages
of NK cell development, such that CD56bright cells are precursors
of CD56dim cells, which represent the most differentiated and
mature NK cell type (Freud and Caligiuri, 2006).
Distinct stages of NK cell maturation can be also distinguished
in the mouse, on the basis of the expression of CD11b and CD27
and the progressive acquisition of Ly49 receptors and effector
functions (Hayakawa et al., 2006). CD11bloCD27hi NK cells
are immature cells preferentially located in bone marrow.
CD11bhiCD27hi NK cells, present in the spleen, liver, and lymph
nodes, are mature cells that secrete IFN-g and are highly cyto-
lytic. CD11bhiCD27lo NK cells have limited lytic capability, reside
mainly in peripheral tissues such as the lungs, andmay represent
senescent cells. Developmental origin also contributes tomurine
NK cell diversity. In addition to classical bone-marrow-derived
NK cells, NK cells with thymic origin have recently been recog-
nized (Di Santo, 2008). These cells express the a subunit of theImmunity 31, July 17, 2009 ª2009 Elsevier Inc. 15
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ReviewFigure 1. Human and Mouse IL-22 Producing NK and LTi-like Cells in the Gut and Secondary Lymphoid Organs
Human IL-22-producing NK cells (left) include CD56+NKp44+ and CD56NKp44+ NK cells. Both populations are present in secondary lymphoid organs such as
Peyer’s Patches (PPs) and tonsils (not shown); they are also present, but much less frequent, in the intestinal lamina propria. Human fetal LTi cells are present in
mesenteric lymph nodes (MLNs) and produce both IL-22 and IL-17; they differentiate into LTi-like cells that express CD56 and secrete IL-22 and IL-17. Mouse
IL-22-producing NK cells (right) include NKp46+CD127+c-Kit+NK1.1 and NKp46+CD127+c-Kit+NK1.1+ cells. These cells are present in PPs and the intestinal
lamina propria; they may also be present in cryptopatches that are generated between crypts in the intestinal lamina propria (not shown), although this remains
somewhat controversial. Mouse LTi-like cells are present in the spleen and in the intestinal lamina propria; they express CD4, CD127, and CCR6 and produce
IL-22 and IL-17. Half of these cells also express CXCR5 and CCR7 (not shown).receptor for IL-7 (IL-7Ra or CD127), CD69, and the transcription
factor GATA3, and they preferentially home to the lymph nodes.
NK cell diversity also depends on anatomical location. During
pregnancy, both the human and murine placentas house unique
subsets of NK cells that contribute to successful implant and
function of the placenta by secreting angiogenetic factors,
such as vascular endothelial growth factor (VEGF) (Croy et al.,
2003; Manaster and Mandelboim, 2008). However, until now,
little attention has been paid to NK cell diversity in the mucosae.
A few studies have investigated murine NK cells in the lamina
propria of the gut and tonsils, with reported functions similar to
those of classical NK cells (Chinen et al., 2007; Munz, 2008).
More recently, however, a string of papers has emerged, detail-
ing an unexpected diversification of NK cell function in the gut
mucosa (Figure 1).
A Gut NK Cell Subset with Unique Markers
and the Capacity to Secrete IL-22
In one study, analysis of human tonsils and Peyer’s Patches
(PPs) revealed an NK cell subset expressing the receptor
NKp44, a marker that is absent on circulating NK cells (Cella
et al., 2009)(Table 1). NKp44+ cells are predominantly found in
the mucosal areas covering the lymphoid aggregates (Figure 1).
Consistent with their mucosal localization, NKp44+ cells express
the chemokine receptor CCR6, which promotes leukocyte16 Immunity 31, July 17, 2009 ª2009 Elsevier Inc.homing to the gut mucosa (Williams, 2006). In addition,
NKp44+ cells secrete CCL20, the ligand for CCR6, suggesting
that these NK cells can promote their own accumulation. Tran-
scriptional and functional profiles reveal that mucosal NKp44+
cells are not proficient at typical NK cell functions such as
release of perforin and IFN-g. Instead, NKp44+ cells isolated
from the mucosae produce IL-22.
IL-22 is a member of the family of IL-10-related cytokines,
which protects the epithelial cell barrier in the gut and other
mucosal surfaces from pathogens (Aujla and Kolls, 2009;
Kotenko, 2002; Wolk and Sabat, 2006; Zenewicz and Flavell,
2008). The receptor for IL-22, which is exclusively expressed
on epithelial cells, initiates a signal transducer and activator of
transcription (STAT) 3 signaling pathway that induces the
production of antimicrobial molecules such as b-defensin-2,
b-defensin-3, S100A7, calgranulins S100A8 and S100A9, Re-
gIIIb, RegIIIg, and lipocalin-2 (Aujla et al., 2008; Liang et al.,
2006; Wolk et al., 2004; Zheng et al., 2008). Additionally, IL-22
stimulates epithelial cells to secrete the antiinflammatory cyto-
kine IL-10 (Nagalakshmi et al., 2004b). Because of these
combined actions, IL-22 can protect the gut in a model of extra-
cellular bacterial infection caused by Citrobacter rodentium
(C. rodentium) (Zheng et al., 2008) and in a model of ulcerative
colitis (Sugimoto et al., 2008). In addition, IL-22 induces hepato-
cytes to secrete acute phase proteins such as serum amyloid A
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ReviewTable 1. Characteristics of IL-22-Producing NK Cells and LTi-like Cells in Human and Mouse
Name Phenotype
Cyto-
kines Location
Chemokine
Receptors
and
Chemokines
Transcription
Factors
Genetic Mutations
Affecting
Development
or Function
Human
NK-22 CD3-CD56+NKp44+c-Kit+ IL-22 tonsil, PPs CCR6, CCL20 RORgt, AHR,
RORa, IRF4
NK stage 3 (iNK) CD34CD56NKp44+
c-Kit+CD94
IL-22 tonsil
LTi CD4linCD127+CD45int
c-Kit+CD161+CD7+
IL-17,
IL-22
fetal
mesentery,
MLNs,
PLNs
CCR7 RORgt, TCF3,
Id2
LTi-like (iNK?) CD34CD56+CD127+c-Kit+ IL-17,
IL-22
fetal
MLNs,
postnatal
tonsil
Mouse
RORgt+NKp46+NK1.1 CD3CD127+c-Kit+CD122lo
CD11bCD27Ly49A/D
NKG2DloCD94
IL-22,
GM-CSF
PPs, LP,
IELs, CPs
CCR7, CXCL2 RORgt, RORa RorcGFP/GFP,
Rag2/Il2rc/
RORgt+NKp46+NK1.1+ CD3CD127+c-
Kit+CD122loCD11bCD27/+
Ly49A/DNKG2D+CD94+
IL-22,
GM-CSF
PPs, LP,
IELs, CPs
RORgt, Id2 Rag2/Il2rb/,
Il15/,
Rag2/Il2rc/
LTi-like CD4+CD3NK1.1CD11b
Gr1CD11cB220
IL-17,
IL-22
Spleen, LP CCR6, CXCR5,
CCR7
RORgt, AHR,
STAT3
Rag2/Il2rc/,
Stat3fl/flMMTVCre
Abbreviations are as follows: PPs, Peyer’s Patches; MLNs, mesenteric lymph nodes; PLNs, peripheral lymph nodes; LP, intestinal lamina propria; IELs,
intraepithelial lymphocytes; CPs, cryptopatches.and LPS-binding protein (Dumoutier et al., 2000; Wolk et al.,
2007) and protects the liver in a mouse model of acute hepatitis
(Zenewicz et al., 2007). Intriguingly, IL-22 has also been shown to
play a role in the pathogenesis of autoimmune disease, such as
psoriasis, by exerting a proinflammatory effect (Boniface et al.,
2005; Ma et al., 2008; Wolk et al., 2009; Wolk et al., 2006; Zheng
et al., 2007). However, this pathogenic effect is likely to reflect
dysregulated duration and/or amount of IL-22 secretion.
NKp44+ NK cells also produce IL-26 and the leukemia inhibi-
tory factor (LIF). IL-26 is another IL-10-related cytokine that is
present only in humans. The receptor for IL-26 is predominantly
expressed on epithelial cells, and therefore IL-26, like IL-22, acts
mainly on epithelial cells, inducing STAT3 andSTAT3-dependent
pathways that promote cutaneous and mucosal immunity (Hor
et al., 2004; Nagalakshmi et al., 2004a). The LIF activates
STAT3 and, among other functions, has been reported to protect
the lung alveolar epithelium in a model of bacterial infection
(Quinton et al., 2008). Remarkably, although IL-22 and IL-26
are frequently produced together with IL-17 by CD4+ T helper
17 (Th17) cells (Chung et al., 2006; Liang et al., 2006; Wilson
et al., 2007), NKp44+ cells do not produce IL-17 (Cella et al.,
2009).
Corresponding analysis of NK cells in the murine gut yielded
very similar findings (Table 1) (Cella et al., 2009; Luci et al.,
2009; Sanos et al., 2009; Satoh-Takayama et al., 2008). Analysis
of NK cells in the lamina propria and intraepithelial surfaces of the
mouse small intestine with the use of multiple markers such as
NKp46, NK1.1, CD127, and c-Kit (not NKp44, which is onlyexpressed in humans) revealed substantial heterogeneity. A
subpopulation of NKp46+ cells express CD127 (IL-7Ra) and
c-Kit, lack Ly49 receptors, and are poor producer of perforin
and IFN-g (Figure 1). Interestingly, the classical NK cell marker
NK1.1 is expressed only on a small subset of these cells. Func-
tional characterization of NKp46+CD127+c-Kit+NK1.1 and
NKp46+CD127+c-Kit+NK1+ cells confirmed expression of the
IL-22 transcript (Luci et al., 2009; Satoh-Takayama et al., 2008)
and protein (Cella et al., 2009; Sanos et al., 2009), comparable
to human NKp44+ cells (Figure 1). Moreover, NKp46+CD127+
c-Kit+NK1.1 and NKp46+CD127+c-Kit+NK1.1+ cells express
the GM-CSF transcript (Satoh-Takayama et al., 2008) (Table 1).
A second subpopulation of NKp46+ cells lacks CD127 and bears
features typical of classical NK cells, such as coexpression of
NK1.1, various Ly49 receptors, perforin, and IFN-g. Collectively,
these studies demonstrate the conservation of a unique NK cell
subset that specializes in IL-22 secretion in both humans and
mice.
Developmental Requirements of Gut NK Cells: RORgt,
Other Transcription Factors, and Intestinal Microbiota
Functional differentiation of T cells and NK cells relies on unique
transcription factors that induce the production of distinctive
cytokines that direct immune responses (Weaver and Murphy,
2007; Di Santo, 2008). Accordingly, a major issue that arises in
the study of NK cell subsets is identifying the transcription
factors responsible for their differentiation. Which transcription
factors selectively drive the differentiation of IL-22-producingImmunity 31, July 17, 2009 ª2009 Elsevier Inc. 17
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role of the retinoic acid receptor-related orphan receptor gamma
t (RORgt) for at least two reasons. First, RORgt is essential for
differentiation of CD4+ Th17 cells (Ivanov et al., 2007), which
frequently produce IL-22 (Chung et al., 2006; Liang et al.,
2006; Wilson et al., 2007). Second, RORgt is expressed in
lymphoid tissue inducer (LTi) cells, which somewhat resemble
IL-22-producing NK cells phenotypically for the expression of
CD127 and c-Kit and are located in similar areas in the gut of
adult mice (Eberl and Littman, 2003). Indeed, IL-22-producing
NK cells from both mice (Luci et al., 2009; Sanos et al., 2009; Sa-
toh-Takayama et al., 2008) and humans (Cella et al., 2009)
express RORgt. The analysis of gene-targeted mice expressing
GFP under control of the RORgt promoter (Rorc-Gfp+/) further
demonstrates that many RORgt+ cells in the mouse gut corre-
spond to the IL-22-secreting NKp46+CD127+c-Kit+NK1.1+/
cells (Luci et al., 2009; Satoh-Takayama et al., 2008). Most
importantly, IL-22-producing NK cells are reduced in Rorc/
mice (Satoh-Takayama et al., 2008), corroborating the observa-
tion that RORgt is important for development of these cells.
Gut NK cells express additional Th17 cell transcription factors,
including the arylhydrocarbon receptor (AHR) (Cella et al., 2009),
which has been implicated in the induction of IL-22 in T cells
(Kimura et al., 2008; Veldhoen et al., 2008), RORa (Cella et al.,
2009; Luci et al., 2009), and interferon regulatory factor (IRF) 4
(Cella et al., 2009). Interestingly, numbers of NKp46+CD127+
NK1.1 cells are strongly reduced in germ-free mice (Sanos
et al., 2009; Satoh-Takayama et al., 2008), suggesting that
intestinal microbes influence the development of these IL-22-
producing NK cells. In contrast, NKp46+CD127+NK1.1+ cells
are maintained in germ-free mice. Recently, Veldhoen and
colleagues showed that metabolic transformation of tryptophan
generates compounds that act as AHR ligands (Veldhoen et al.,
2009). Thus, it is possible that the intestinal microbiota generates
arylhydrocarbon metabolites that activate AHR, promoting the
differentiation of many IL-22-producing NK cells.
Development of classical NK cells requires IL-15 and its
receptor, which consists of a complex of IL-15Ra, IL-2Rb, and
common gamma chain (gc) (Di Santo, 2008). Accordingly, clas-
sical NK cells are severely reduced in Il15/, Il2rb/, or
Il2rc/ mice (Satoh-Takayama et al., 2008). Of the IL-22-pro-
ducing NK cells, the NKp46+CD127+NK1.1+ population requires
IL-15 signaling. In contrast, NKp46+CD127+NK1.1 cells are
maintained in Il15/ or Il2rb/ mice (Satoh-Takayama et al.,
2008), but are ablated in Il2rc/ mice, suggesting the require-
ment of a gc-associated cytokine receptor distinct from IL-
15R, most likely IL-7R. Altogether, these observations suggest
that most of the IL-22-producing NK cells utilize a unique devel-
opmental pathway relative to classical NK cells. However, the
conventional NK cell development may also generate some
IL-22-producing NK cells.
IL-22-Producing NK Cells Are Highly Responsive
to IL-23
What is the specific nature of the stimuli that trigger the secretion
of IL-22 by NK cells? Given the reduction of IL-22 production in
Il23/ mice during C. rodentium infection (Zheng et al., 2008),
the role of IL-23 in the differentiation of Th17 cells that also
produce IL-22 (Aggarwal et al., 2003; Cua et al., 2003; Veldhoen18 Immunity 31, July 17, 2009 ª2009 Elsevier Inc.et al., 2006a) and the capacity of RORgt signaling to induce
expression of IL-23 receptor (IL-23R) (Chen et al., 2007), IL-23
emerges as an obvious candidate. Indeed, IL-23 is the most
effective trigger of IL-22 secretion by both human (Cella et al.,
2009) and mouse (Cella et al., 2009; Sanos et al., 2009) gut NK
cells. Notably, IL-23 exerts distinct effects on NK and Th17 cells.
Although IL-23 only promotes expansion and maintenance of Th
17 cells (Aggarwal et al., 2003; Cua et al., 2003; Veldhoen et al.,
2006a), IL-23 alone is sufficient to induce IL-22 secretion by NK
cells. This prompt IL-22 production in response to IL-23 is remi-
niscent of the capacity of gd T cells and invariant natural killer T
(iNKT) cells to secrete IL-17 upon acute exposure to IL-23 (Lock-
hart et al., 2006; Michel et al., 2007; Michel et al., 2008; Rachit-
skaya et al., 2008; Shibata et al., 2007; Umemura et al., 2007).
IL-22 secretion by gut NK cells can be partially induced by IL-6
and IL-15 (Cella et al., 2009). In contrast, IL-12, which stimulates
IFN-g secretion in conventional NK cells (Trinchieri, 2003), does
not induce IL-22, at least in human mucosal NK cells (Cella et al.,
2009). These data designate a clear functional bifurcation within
NK cell populations, such that conventional NK cells respond to
IL-12 and secrete IFN-g, whereas mucosal NK cells that secrete
IL-22 selectively respond to IL-23.
It is noteworthy that IL-23 promotes autoimmunity in mouse
models of inflammatory bowel disease (IBD) (Ahern et al.,
2008; Kullberg et al., 2006), experimental autoimmune encepha-
lomyelitis (EAE) (Cua et al., 2003; Veldhoen et al., 2006b), and
arthritis (Murphy et al., 2003). Moreover, genome association
studies have identified IL-23R polymorphisms associated with
resistance to IBD in humans (Duerr et al., 2006). It has been
proposed that dysregulation of IL-23 may cause autoimmunity
through excessive differentiation of proinflammatory Th17 cells
(Bettelli et al., 2008; McGeachy and Cua, 2007). However, the
discovery that IL-23 induces secretion of IL-22 by a subset of
NK cells that do not secrete IL-17 complicates the pathogenic
role of IL-23 in autoimmunity. It is possible that a protective
host response to pathogen invasion requires a balanced
response of the IL-23-IL-17 and the IL-23-IL-22 axes. The
elevated expression of IL22 mRNA in inflamed colonic lesions
and the high amounts of IL-22 in the serum of patients with
Crohn’s disease (Brand et al., 2006) may reflect an attempt by
the host immune response to regain homeostasis. Alternatively,
an excessive IL-22 response may contribute to disease, as
recently shown for psoriasis (Ma et al., 2008; Wolk et al., 2009;
Zheng et al., 2007). Most likely, IL-22 is a double-edged sword
that contributes to host defense but can also induce pathology
in certain conditions.
A Protective Role for IL-22-Producing NK Cells
in Autoimmunity and Host Defense
Does IL-22 have a protective role in IBD? Are NK cells an impor-
tant source of IL-22? Flavell and colleagues specifically
addressed these questions in a colitis model initiated by the
transfer of CD4+CD45RBhi T cells into Rag1/ recipient mice
(Zenewicz et al., 2008). Colitogenic T cells arising in this context
promoted expression of IFN-g, IL-17, and IL-22. For determining
whether IL-22 had a protective role in thismodel, CD4+CD45RBhi
T cells derived from either Il22+/+ or Il22/mice were adoptively
transferred intoRag1/ orRag1/Il22/mice. The absence of
both exogenous T cell-derived and endogenous non-T non-B
Immunity
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mortality, and destruction of colonic tissue than did the lack of
either the exogenous T cell-derived source or the endogenous
source of IL-22. Flavell and colleagues went on to identify which
endogenous non-T non-B cells produced IL-22. NK cells were
identified as a likely candidate for several reasons: (1) IL-23
induced IL-22 in splenic NK subsets; (2) NK cells infiltrated the
inflamed colon; and (3) there was a drop in intestinal IL-22
content when Il22/ CD45RBhi cells were transferred into
Rag1/ Il2rg/ recipient mice, which lack all NK cells, rather
than into Rag1/ recipients. The role of NK cells as a source
of IL-22 in protection from IBD was further corroborated in the
dextran sodium sulfate (DSS)-induced colitis model, which impli-
cates the innate immune system rather than T cells. DSS treat-
ment induced production of IL-22, and the disease was more
severe in Il22/mice than in WT mice. Moreover, IL-22 expres-
sionwas reduced in the inflamed colon after depletion of NK cells
via anti-NK1.1 and -asialoGM1 (Zenewicz et al., 2008).
Because IL-22 has a protective effect against intestinal
C. rodentium infection inRag2/mice, which lack T cell sources
of IL-22 (Zheng et al., 2008), IL-22-secreting NK cells may
provide an important source of IL-22 in this model. Indeed, NK
cell depletion with anti-NK1.1 increased the severity of this
type of infection (Cella et al., 2009; Satoh-Takayama et al.,
2008). Altogether, these studies suggest a protective role of
IL-22-producing NK cells in host defense and autoimmunity. It
should be noted, however, that NK1.1 and asialoGM1 are ex-
pressed by classical NK cells, but only by a limited and variable
percentage of IL-22-producing NK cells. Therefore, the depletion
of these cells by anti-NK1.1 or -asialoGM1 treatments may have
been partial and nonspecific in these studies. Development of
more specific reagents will be necessary in providing a definitive
assessment of the role of IL-22-producing NK cells in host
defense and autoimmunity.
LTi Cells as Innate Sources of IL-17 and IL-22
LTi cells are rare cells involved in the formation of secondary
lymphoid organs, including lymph nodes and gut-associated
PPs (Vondenhoff et al., 2007). These cells lack lineage markers
(lin) and express CD4, lymphotoxin a1b2 (Lta1b2), and the che-
mokine receptors CCR7 and CXCR5 (Mebius et al., 1997). LTi
differentiation depends on the transcription factors RORgt (Sun
et al., 2000) and inhibitor of differentiation 2 (Id2) (Yokota et al.,
1999). In addition, LTi cells require the IL-7 receptor and the
associated gc chain for their function (Adachi et al., 1997; Yosh-
ida et al., 1999). IL-7-IL-7R signaling induces the expression of
Lta1b2, which engages the lymphotoxin b receptor (LTbR) on
stromal cells. LTbR signaling converts stromal cells into stromal
organizers expressing ICAM1, VCAM1, and the chemokines
CCL19, CCL21, and CXCL13. Together, LTi and stromal orga-
nizers attract hematopoietic cells, promoting lymphoid organo-
genesis.
Two studies recently showed that human LTi cells and mouse
LTi-like cells secrete IL-17 and IL-22. O’Shea and colleagues
asked whether IL-23 can induce IL-17 secretion in splenocytes
(Takatori et al., 2009). Although IL-17 is thought to be secreted
mainly by CD4+ and CD8+ T cells, iNKT cells, and gd T cells,
these authors found that IL-23 induces IL-17 secretion by
Rag2/ splenocytes, which lack all T cells. In contrast, IL-17production was completely abrogated in Rag2/Il2rg/ sple-
nocytes, which also lack NK cells. This result suggested that
IL-17 can be produced by a non-T non-B cell, possibly an NK
cell or a myeloid cell. No IL-17 was detected in NK1.1+ cells,
DCs, or plasmacytoid DCs by intracellular staining of Rag2/
splenocytes. However, IL-17 was detected in LinCD4+ cells
that resembled LTi cells, in that they all expressed RORgt and
IL-7Ra (CD127), and about half expressed CCR7 and CXCR5,
as well (Figure 1 and Table 1). The capacity of these LTi-like cells
to produce IL-17 was confirmed in vivo. Injection of Zymosan,
a TLR2 and Dectin-1 agonist that triggers the secretion of
IL-23 by DCs, macrophages, and monocytes (Gerosa et al.,
2008; LeibundGut-Landmann et al., 2007), induced high
amounts of IL-17 in the serum and spleen ofRag2/mice. Inter-
estingly, spleen LTi-like cells and IL-22-producing NK cells share
some remarkably similar molecular and functional signatures.
LTi-like cells produced IL-22 in response to IL-23, and some of
the IL-22-producing cells were NK1.1+ cells (Takatori et al.,
2009). Additionally, LTi-like cells expressed the transcription
factor AHR and the chemokine receptor CCR6, which mediates
homing to the mucosae. Accordingly, LTi-like cells were found
not only in the spleen but also in the intestinal lamina propria
(Takatori et al., 2009). Together, these observations demonstrate
that mouse LTi-like cells provide an innate source of IL-17 and
IL-22 located in the spleen, as well as in the intestinal lamina
propria.
In another study, Cupedo and colleagues identified human LTi
as a source of IL-17 and IL-22. Human LTi cells were isolated
from first-trimester mesentery and second-trimester developing
lymph nodes as LinCD127+CD45int cells (Figure 1) (Table 1)
(Cupedo et al., 2009). Likemouse LTi cells, these cells expressed
LTA, LTB, RORC, Id2, and CCR7 transcripts, but not CD4. For
demonstration of LTi function, LinCD127+CD45int cells were
isolated and incubated in vitro with fetal mesenchymal stem cells
expressing LTbR and tumor necrosis factor receptor II
(TNFRSF1B). LinCD127+CD45int cells induced the differentia-
tion of mesenchymal cells into stromal organizers expressing
ICAM-1 and VCAM1 through the LTbR and the TNFRSF1B
signaling pathway, demonstrating LTi activity. The expression
of NK cell markers, such as CD161 and CD7, on LTi cells sug-
gested a potential connection between LTi andNK cells. Accord-
ingly, in several culture conditions, LinCD127+CD45int cells
differentiated into CD3CD56+CD127+ NK cells that expressed
NKp46, NKp30, and NKp44 but lacked expression of KIRs,
CD94, NKG2D, perforin, and granzyme A. LTi (CD127+CD56)
and CD56+CD127+ cells were also isolated ex vivo from fetal
humanmesenteric lymph nodes. LTi and CD56+CD127+ NK cells
both expressed IL-17A and IL-22 transcripts, similar to murine
LTi-like cells (Figure 1). Moreover, LTi cells and CD56+CD127+
NK cells capable of producing IL-17 and IL-22 after stimulation
with PMA plus ionomycin were also found in postnatal tonsils.
Taken together, studies in mice and humans indicate that LTi
and LTi-like cells may be involved not only in the development
of lymphoid tissues but also in host responses to pathogens
through release of IL-17 and IL-22.
Unresolved Issues and Future Challenges
The exciting discovery of LTi-like and mucosal NK cells that
produce IL-17 and/or IL-22 opens a new area of investigationImmunity 31, July 17, 2009 ª2009 Elsevier Inc. 19
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tion is whether these cells represent distinct cell types or are
somewhat developmentally related. On one hand, LTi and LTi-
like cells produce IL-17, whereas mucosal NK cells do not.
Thus, these cells are functionally distinct. On the other hand,
LTi-like and mucosal NK cells share many transcription factors
and signaling pathways, including RORgt, AHR, and IL-7R.
Thus, it is possible that these cells originate from one precursor
cell that generates both IL-17- and IL-22-producing LTi-like cells
and IL-22-producing NK cells through divergent pathways
(Figure 2). Alternatively, LTi-like and mucosal NK cells may
correspond to sequential developmental stages of the same
cell type (Figure 2). In support of this possibility, an original study
byMoebius demonstrated that LTi cells can generate NK1.1+ NK
cells and CD11c+ DCs but not B or T cells in vitro (Mebius et al.,
1997).
Can IL-22-producing NK cells be generated in part within the
conventional NK cell-development pathway? Human NK cells
develop through five stages, based on the differential expression
of CD34, c-Kit, CD94, and CD56. CD34 is expressed at stages 1
and 2, c-Kit at stages 2 and 3, CD94 at stage 4, CD56 at stages 4
and 5 (Freud and Caligiuri, 2006). A recent study found that stage
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Figure 2. Developmental Pathways for
IL-22-Producing NK and LTi-like Cells in
Humans and Mice
It is possible that both cell types originate from
an LTi cell precursor that generates both IL-17-
and IL-22-producing LTi-like cells and IL-22-
producing NK cells through divergent pathways.
Alternatively, LTi-like and IL-22-producing NK
cells may correspond to sequential developmental
stages of the same cell type. A subset of IL-22-
producing NK cells (stage 3 NK precursors in hu-
mans and NKp46+CD127+NK1.1+ in mice) could
branch off the developmental pathway of classical
NK cells. Putative pathways are indicated in blue
and dashed arrows; established pathways are
indicated in yellow and solid arrows.
3 NK cell precursors, defined as
CD56CD34cKit+CD94 cells, express
IL-22 and IL-26 but not IL-17A or IL-17F
(Hughes et al., 2009). Thus, it is possible
that some of these NK cell precursors
continue to produce IL-22 indefinitely
whereas others go on to stage 4 to
become classical CD56+ NK cells
producing IFN-g. In the mouse, IL-22-
producingNKcells include amajor subset
of NK1.1 cells that is IL-15-independent,
but also a minor subset of NK1.1+ cells
that appears to be IL-15-dependent
(Satoh-Takayama et al., 2008). Thus, this
latter subset could branch off the devel-
opmental path of classical NK cells
(Figure 2).
Although LTi-like cells and mucosal NK
cells share several molecules involved in
differentiation, such as RORgt, AHR,
and IL-7R, and may originate through
related pathways, the factors that induce commitment toward
one or the other cell type remain to be clarified. The anatomical
site of differentiation (spleen, lymph nodes, gut), the presence of
commensal flora, and the occurrence of microbial infectionsmay
be crucial factors. Whereas IL-22-secreting NK cells absolutely
require the influence of commensal bacteria (Sanos et al.,
2009; Satoh-Takayama et al., 2008), LTi and LTi-like cells
develop in the fetus mesentery and in the postnatal spleen
(Cupedo et al., 2009; Takatori et al., 2009), which are not directly
exposed to bacterial components. Interestingly, it has been
shown that after birth, LTi-like cells form hundreds of small cell
clusters, termed cryptopatches (CPs), between crypts in the
intestinal lamina propria. During subsequent bacterial coloniza-
tion, CPs recruit other hematopoietic cells, particularly B cells,
to develop into larger aggregates known as isolated lymphoid
follicles (ILFs) (Bouskra et al., 2008; Pabst et al., 2005). Thus,
the intestinal microbiota may be essential for inducing the differ-
entiation and/or the accumulation of mucosal NK cells within
ILFs, as well as in larger aggregates, such as PPs.
The cytokine microenvironment may also influence the differ-
entiation of double IL-17-IL-22-producing LTi-like cells versus
IL-22-only-producing NK cells. Studies in T cells have shown20 Immunity 31, July 17, 2009 ª2009 Elsevier Inc.
Immunity
Reviewthat IL-17 and IL-22 are not coregulated. Whereas IL-6 and
transforming growth factor (TGF)-b are both required for induc-
tion of Th17 cells, IL-6 alone can induce IL-22 in T cells, whereas
TGF-b inhibits IL-6-mediated induction of IL-22 (Zheng et al.,
2007). Th 17 cells can also lose the capacity to produce IL-17,
reverting to IFN-g-producing T cells (Lee et al., 2009). Thus,
LTi-like cells may spontaneously convert into IL-22-only-
producing NK cells.
Another important question for future studies is whether LTi-
like cells and IL-22-producing NK cells have overlapping or
entirely distinct locations. Human LTi cells are present in mesen-
teric lymph nodes and tonsils (Cupedo et al., 2009). Mouse LTi-
like cells are found in the spleen and the intestinal lamina propria
(Takatori et al., 2009). Both human and mouse IL-22-producing
NK cells are present in the subepithelial areas of mucosal-asso-
ciated lymphoid aggregates, such as tonsils and PPs (Cella et al.,
2009; Luci et al., 2009). Fewer NK cells are also found in the
intestinal lamina propria, within the intestinal epithelium (Cella
et al., 2009; Luci et al., 2009; Sanos et al., 2009; Satoh-
Takayama et al., 2008) and in colonic crypts (Luci et al., 2009).
However, the presence of IL-22-producing NK cells in CPs is
controversial, because it was confirmed in two studies (Luci
et al., 2009; Sanos et al., 2009) but excluded by another study
(Satoh-Takayama et al., 2008). This discrepancy may be due
to the different sensitivity of the techniques used for detecting
IL-22-producing NK cells. Alternatively, the discrepancy may
reflect the insufficiency of phenotypic criteria to distinguish
LTi cells, which are found in CPs (Bouskra et al., 2008), from
IL-22-secreting NK cells, which may be present in larger
lymphoid aggregates. To address this issue, it will be essential
to identify LTi-like cells and IL-22-secreting NK cells on the basis
of both their phenotype and their function, either by detecting
intracellular IL-22 and IL-17 or through the generation of reporter
mice in which GFP is driven by the IL-22 or the IL-17 promoter.
Whereas IL-22 produced by NK cells appears to be protective
in mouse models of infections by extracellular bacteria and IBD,
recent studies suggest that LTi cells have a role in restoring the
integrity of lymphoid organs after viral infection (Scandella
et al., 2008). Thus, it will be important to examine the relative
impact of NK and LTi-like cells on host defense and autoimmu-
nity in the mucosae. For this, it will be essential to selectively
eliminate IL-22-producing LTi-like and NK cells by developing
appropriate antibodies or genetically modified mice. Finally,
although many studies have focused on gut NK cell subsets,
there is some evidence that NK cell subsets can be identified
in the skin (Luci et al., 2009), and it is likely that more NK cell
subsets will be found in the mucosae of the respiratory and
urogenital tracts. Further exploration of NK cell diversity may
bring fresh and unexpected insight into NK cell function in immu-
nity, extending the horizon beyond anticancer surveillance and
antiviral responses.
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